ArticleFrontiers in oncology2025

Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen.

Daniel Sentana-Lledo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.